Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Diagnostics (Basel) ; 13(19)2023 Oct 03.
Article in English | MEDLINE | ID: mdl-37835862

ABSTRACT

Bladder cancer (BCa) is a common type of cancer that affects the urinary bladder. The early detection and management of BCa is critical for successful treatment and patient outcomes. In recent years, researchers have been exploring the use of biomarkers as a non-invasive and effective tool for the detection and monitoring of BCa. One such biomarker is programmed death-ligand 1 (PD-L1), which is expressed on the surface of cancer cells and plays a crucial role in the evasion of the immune system. Studies have shown that the PD-L1 expression is higher in BCa tumors than in healthy bladder tissue. Additionally, PD-L1 expression might even be detected in urine samples in BCa patients, in addition to the examination of a histological sample. The technique is being standardized and optimized. We reported how BCa patients had higher urinary PD-L1 levels than controls by considering BCa tumors expressing PD-L1 in the tissue specimen. The expression of PD-L1 in urinary BCa cells might represent both a diagnostic and a prognostic tool, with the perspective that the PD-L1 expression of exfoliate urinary cells might reveal and anticipate eventual BCa recurrence or progression. Further prospective and longitudinal studies are needed to assess the expression of PD-L1 as a biomarker for the monitoring of BCa patients. The use of PD-L1 as a biomarker for the detection and monitoring of BCa has the potential to significantly improve patient outcomes by allowing for earlier detection and more effective management of the disease.

2.
Chir Ital ; 57(1): 99-102, 2005.
Article in Italian | MEDLINE | ID: mdl-15832745

ABSTRACT

The authors report a rare case of composite tumour of the stomach in a 53-year-old woman documenting the neuroendocrine and glandular features of the tumour by means of immunohistochemical investigations. The authors examine the diagnostic and therapeutic possibilities currently available for the management of this group of rare tumours of uncertain histogenesis. They conclude in favour of elective surgical treatment depending on the site and stage of the tumour in keeping with the data reported in the literature. They also discuss the prognosis of such tumours.


Subject(s)
Carcinoid Tumor/pathology , Stomach Neoplasms/pathology , Carcinoid Tumor/diagnosis , Carcinoid Tumor/surgery , Female , Humans , Immunohistochemistry , Middle Aged , Prognosis , Stomach Neoplasms/diagnosis , Stomach Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...